ArticleIEEE transactions on ultrasonics, ferroelectrics, and frequency control2021
Histotripsy for the Treatment of Cholangiocarcinoma Liver Tumors: In Vivo Feasibility and Ex Vivo Dosimetry Study.
Article in IEEE transactions on ultrasonics, ferroelectrics, and frequency control, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 37 citations in OpenAlex.
- Quantification of Histotripsy Dosage Using Machine Learning-Enhanced Ultrasound Imaging Analysis: Correlation with Histological Outcomes.Academic radiology · 2026Article
- Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma.Discover oncology · 2026Review
- Safe and Effective Histotripsy Ablation of Human Liver Tumors in a Genetically Modified Porcine Model.Cancers · 2026Article
- A systematic comparison of cavitation regimes and histotripsy efficiency across pulse duration and repetition rate in a fibrous tissue mimicking phantom.Research square · 2026Article
- The Potential and Challenges of Focused Ultrasound-Mediated Therapies in the Management of Liver and Biliary Tract Cancers.Cancers · 2026Review
- Shock-scattering micro-histotripsy-aided fine needle aspiration for enhanced biomarker profiling and cytopathology.Nature communications · 2026Article
- Histotripsy dose impacts tumor cellular damage and treatment outcomes in a preclinical model of hepatocellular carcinoma.Scientific reports · 2026Article
- Understanding histotripsy ablation safety: a systematic review of pre-clinical and clinical adverse events.CVIR oncology · 2026Review
- Review
- Surgery Without Scalpel: Histotripsy as a Non-Invasive and Non-Thermal Modality for Liver Tumor Ablation.Journal of clinical medicine · 2025Review
- Review
- Development of Histotripsy as a Local-Regional Liver Cancer Therapy: Preclinical to Clinical Translation.Radiology. Imaging cancer · 2025Review
- Therapeutic Advances in Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma: Emerging Treatments and the Role of Liver Transplantation.Current oncology (Toronto, Ont.) · 2025Review
- Revolutionizing cardiovascular care: the power of histotripsy.Journal of ultrasound · 2024Review
- Ultrasonic Nakagami imaging for automatically positioning and identifying the treated lesion induced by histotripsy.Ultrasonics sonochemistry · 2024Article
- In Vivo Cavitation-Based Aberration Correction of Histotripsy in Porcine Liver.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2024Article
- Histotripsy: A Method for Mechanical Tissue Ablation with Ultrasound.Annual review of biomedical engineering · 2024Review
- Advances in Tumor Management: Harnessing the Potential of Histotripsy.Radiology. Imaging cancer · 2024Review
- Histotripsy: an innovative approach for minimally invasive tumour and disease treatment.Annals of medicine and surgery (2012) · 2024Review
- Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Histotripsy is a noninvasive, nonionizing, and nonthermal focused ultrasound ablation method that is currently being developed for the treatment of liver cancer. Promisingly, histotripsy has been shown for ablating primary [hepatocellular carcinoma (HCC)] and metastatic [colorectal liver metastasis (CLM)] liver tumors in preclinical and early clinical studies. The feasibility of treating cholangiocarcinoma (CC), a less common primary liver tumor that arises from the bile ducts, has not been explored previously. Given that prior work has established that histotripsy susceptibility is based on tissue mechanical properties, there is a need to explore histotripsy as a treatment for CC due to its dense fibrotic stromal components. In this work, we first investigated the feasibility of histotripsy for ablating CC tumors in vivo in a patient-derived xenograft mouse model. The results showed that histotripsy could generate CC tumor ablation using a 1-MHz small animal histotripsy system with treatment doses of 250, 500, and 1000 pulses/point. The second set of experiments compared the histotripsy doses required to ablate CC tumors to HCC and CLM tumors ex vivo. For this, human tumor samples were harvested after surgery and treated ex vivo with a 700-kHz clinical histotripsy transducer. Results demonstrated that significantly higher treatment doses were required to ablate CC and CLM tumors compared to HCC, with the highest treatment dose required for CC tumors. Overall, the results of this study suggest that histotripsy has the potential to be used for the ablation of CC tumors while also highlighting the need for tumor-specific treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.